Defined as affecting less than 1 in 2,000 people, rare diseases impact the lives of over 30 million people in Europe. Earlier this year, the European Commission proposed a Revision of the 20-year old legislation on medicines for children and rare diseases. Blamed for not being flexible enough to integrate technological advances or develop further R&D towards unmet medical needs, the legislation is to be modified with a new incentives’ systems. Looking back at the success stories of the last 20 years, what measures are best to ease the lives of rare diseases patients for the next 20 years?
This event will bring together 25-30 stakeholders from EU institution, patient voices and industry, to discuss how to develop the most effective framework to enable treatment of rare diseases.
